Tag: Gastroesophageal junction cancer
ALX Oncology’s evorpacept gets FDA ODD for gastric cancer and gastroesophageal junction cancer
ALX Oncology said that its CD47 blocker evorpacept has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) in gastric cancer ... Read More
Leap Therapeutics gets FDA orphan status for DKN-01 for gastric and gastroesophageal junction cancer
US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of ... Read More
Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo
Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients ... Read More